Trade

with

Clovis Oncology Inc
(NASDAQ: CLVS)
AdChoices
48.51
+1.75
+3.74%
After Hours :
48.60
+0.09
+0.19%

Open

47.95

Previous Close

46.76

Volume (Avg)

819.96k (758.86k)

Day's Range

47.25-49.37

52Wk Range

35.33-93.33

Market Cap.

1.65B

Dividend Rate ( Yield )

-

Beta

2.44

Shares Outstanding

33.96M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 0

    • Net Income

    • -84.53M

    • Market Cap.

    • 1.65B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -844.07

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.44

    • Forward P/E

    • -

    • Price/Sales

    • 114.94

    • Price/Book Value

    • 3.73

    • Price/Cash flow

    • -16.23

      • EBITDA

      • -83.52M

      • Return on Capital %

      • -23.61

      • Return on Equity %

      • -28.59

      • Return on Assets %

      • -23.61

      • Book Value/Share

      • 13.00

      • Shares Outstanding

      • 33.96M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -827.57

            • 39.38

            • Net Profit Margin

            • -844.07

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 11.20

              • 2.92

              • Quick Ratio

              • 11.13

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.36

              • 2.21

              • Book Value/Share

              • 13.00

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -12.45

                • 188.68

                • P/E Ratio 5-Year High

                • -26.30

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.15

                • 124.82

                • Price/Sales Ratio

                • 105.26

                • 8.72

                • Price/Book Value

                • 3.40

                • 7.95

                • Price/Cash Flow Ratio

                • -16.23

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -28.59

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -23.61

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -28.59

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.03

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -83.77M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -16.23
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  69.36%

                  Mutual Fund Ownership

                  44.05%

                  Float

                  61.77%

                  5% / Insider Ownership

                  4.65%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    1,452,300

                  • -10.51

                  • 4.28

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    928,369

                  • 0.00

                  • 2.73

                  • Oppenheimer Global Fund

                  •  

                    879,320

                  • 35.44

                  • 2.59

                  • Bb Biotech AG

                  •  

                    558,188

                  • 14.34

                  • 1.64

                  • T. Rowe Price Health Sciences Fund

                  •  

                    499,342

                  • 53.86

                  • 1.47

                  • T. Rowe Price New Horizons Fund

                  •  

                    468,769

                  • 24.02

                  • 1.38

                  • Franklin Biotechnology Discovery

                  •  

                    440,300

                  • 40.99

                  • 1.30

                  • iShares Nasdaq Biotechnology

                  •  

                    439,995

                  • 0.24

                  • 1.34

                  • Fidelity® OTC Portfolio

                  •  

                    432,455

                  • 0.00

                  • 1.27

                  • iShares Russell 2000 (AU)

                  •  

                    391,026

                  • 3.58

                  • 1.19

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    4,732,216

                  • -6.13%

                  • 13.93

                  • Domain Associates, LLC

                  •  

                    2,658,539

                  • -5.74%

                  • 7.84

                  • NEA Management Company, LLC

                  •  

                    2,279,781

                  • 0.00%

                  • 6.71

                  • Versant Ventures IV LLC

                  •  

                    1,629,667

                  • -25.00%

                  • 4.81

                  • Vanguard Group, Inc.

                  •  

                    1,343,141

                  • +2.52%

                  • 3.95

                  • T. Rowe Price Associates, Inc.

                  •  

                    1,303,051

                  • +20.99%

                  • 3.84

                  • OppenheimerFunds, Inc.

                  •  

                    1,197,182

                  • +40.75%

                  • 3.52

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Clovis Oncology Inc, a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company engaged in acquiring, developing and commer...morecializing anti-cancer agents in the United States, Europe and other international markets. The Company is considered to be in the development stage as of December 31, 2013. The Company has three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II and Phase III clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. The Company maintains global rights for ...moreCO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.lessless

                  Key People

                  Patrick J. Mahaffy

                  CEO/Co-Founder/Director/President

                  Dr. M. James Barrett,PhD

                  Chairman of the Board/Director

                  Dr. Andrew R. Allen

                  Chief Medical Officer/Executive VP, Divisional/Co-Founder

                  Erle T. Mast

                  Secretary/CFO/Chief Accounting Officer/Executive VP/Co-Founder

                  Gillian C. Ivers-Read

                  Executive VP, Divisional/Other Executive Officer/Co-Founder

                  • Clovis Oncology Inc

                  • 2525 28th Street

                  • Boulder, CO 80301

                  • USA.Map

                  • Phone: +1 303 625-5000

                  • Fax: +1 303 245-0360

                  • clovisoncology.com

                  Incorporated

                  2009

                  Employees

                  74

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: